Royce & Associates LP Reduces Holdings in Insmed Incorporated (NASDAQ:INSM)

Royce & Associates LP lowered its position in shares of Insmed Incorporated (NASDAQ:INSM - Free Report) by 5.3% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 90,027 shares of the biopharmaceutical company's stock after selling 5,000 shares during the period. Royce & Associates LP owned about 0.05% of Insmed worth $6,215,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in INSM. Steward Partners Investment Advisory LLC raised its stake in shares of Insmed by 65.2% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 413 shares of the biopharmaceutical company's stock worth $29,000 after purchasing an additional 163 shares during the last quarter. V Square Quantitative Management LLC boosted its holdings in Insmed by 60.3% during the fourth quarter. V Square Quantitative Management LLC now owns 659 shares of the biopharmaceutical company's stock worth $45,000 after buying an additional 248 shares in the last quarter. Spire Wealth Management acquired a new position in Insmed during the fourth quarter worth about $47,000. Smartleaf Asset Management LLC increased its holdings in Insmed by 98.1% in the fourth quarter. Smartleaf Asset Management LLC now owns 830 shares of the biopharmaceutical company's stock valued at $57,000 after buying an additional 411 shares in the last quarter. Finally, Venturi Wealth Management LLC acquired a new stake in shares of Insmed during the 4th quarter valued at approximately $86,000.

Insider Activity

In other Insmed news, insider Martina M.D. Flammer sold 3,344 shares of the business's stock in a transaction that occurred on Tuesday, January 7th. The shares were sold at an average price of $65.91, for a total transaction of $220,403.04. Following the completion of the sale, the insider now directly owns 102,766 shares in the company, valued at $6,773,307.06. The trade was a 3.15 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Sara Bonstein sold 1,066 shares of the firm's stock in a transaction on Friday, January 10th. The shares were sold at an average price of $63.72, for a total transaction of $67,925.52. Following the completion of the transaction, the chief financial officer now directly owns 118,863 shares in the company, valued at approximately $7,573,950.36. This represents a 0.89 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 550,957 shares of company stock valued at $42,992,528 in the last ninety days. Company insiders own 4.60% of the company's stock.

Remove Ads

Analyst Ratings Changes

INSM has been the topic of a number of research reports. Stifel Nicolaus lowered their price target on Insmed from $97.00 to $96.00 and set a "buy" rating on the stock in a report on Friday, February 21st. JPMorgan Chase & Co. raised their price target on Insmed from $83.00 to $92.00 and gave the company an "overweight" rating in a research report on Friday, February 7th. UBS Group lifted their price target on Insmed from $105.00 to $110.00 and gave the stock a "buy" rating in a research note on Thursday, March 6th. Guggenheim reissued a "buy" rating and issued a $101.00 price objective on shares of Insmed in a research note on Tuesday, February 25th. Finally, Cantor Fitzgerald restated an "overweight" rating on shares of Insmed in a research report on Wednesday, February 19th. One investment analyst has rated the stock with a sell rating and sixteen have given a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $94.00.

Insmed Trading Up 1.5 %

NASDAQ INSM traded up $1.15 during trading hours on Friday, hitting $79.92. 1,928,336 shares of the company's stock were exchanged, compared to its average volume of 2,177,956. The company has a debt-to-equity ratio of 2.03, a quick ratio of 5.99 and a current ratio of 6.37. The firm has a market capitalization of $14.47 billion, a P/E ratio of -14.30 and a beta of 1.28. The business's 50 day moving average is $77.43 and its 200-day moving average is $73.80. Insmed Incorporated has a 12-month low of $21.92 and a 12-month high of $84.91.

Insmed (NASDAQ:INSM - Get Free Report) last released its earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.17) by ($0.15). Insmed had a negative return on equity of 4,773.73% and a negative net margin of 251.24%. The company had revenue of $104.44 million during the quarter, compared to analyst estimates of $102.31 million. As a group, analysts anticipate that Insmed Incorporated will post -4.56 EPS for the current fiscal year.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.